Last updated on June 2018

Observational Registry of H.P. Acthar Gel for Multiple Sclerosis Relapse


Brief description of study

This observational study aims to characterize the patient population and describe multiple sclerosis exacerbation recovery, treatment patterns and safety outcomes in patients with multiple sclerosis experiencing exacerbations treated with H.P. Acthar Gel (Acthar Gel) in standard practice in the United States.

Detailed Study Description

H.P. Acthar Gel (repository corticotropin injection) contains a porcine analogue of adrenocorticotropic hormone (ACTH) for intramuscular or subcutaneous use. H.P. Acthar Gel (Acthar Gel) was initially approved by the FDA in 1952 and has multiple indications of use. This registry will evaluate the use of Acthar Gel for the treatment of exacerbations of multiple sclerosis (MS) in the US.

Clinical Study Identifier: NCT02633033

Contact Investigators or Research Sites near you

Start Over

Sean Ma

Five Towns Neurology
Woodmere, NY United States
0.09miles
  Connect »